Research Institute, Heart Hospital, Sao Paulo, Brazil.
Research Institute, Heart Hospital, Sao Paulo, Brazil.
Surg Obes Relat Dis. 2019 Feb;15(2):211-217. doi: 10.1016/j.soard.2018.11.022. Epub 2018 Nov 27.
Although Roux-en-Y gastric bypass (RYGB) results in significant weight loss and cardiometabolic risk factors improvements; there is no consensus whether limb lengths may influence these results.
To evaluate the correlations between the common limb length (CLL) and hypertension remission rate, cardiometabolic risk factors, and nutritional parameters after RYGB.
Private Hospital, Brazil.
GATEWAY is a randomized trial designed to evaluate the efficacy of RYGB on hypertension improvement and other cardiometabolic risk factors in patients with grade I and II obesity compared with medical therapy. The follow-up was 1 year. We measured the entire bowel in all patients and used a 150-cm alimentary limb and a 100-cm biliopancreatic limb. Univariate logistic regression was used to estimate the relationship between CLL and hypertension remission. Pearson and Spearman correlation were used to evaluate the correlation between the CLL and the percentage changes of cardiometabolic risk factors and nutritional parameters.
From 100 randomized patients, 45 were submitted to RYGB and completed the follow-up. Mean CLL was 466.3 ± 86.4 cm. Of patients, 55.6% from the RYGB group showed remission of hypertension. CLL length was not significantly associated with hypertension remission (odds ratio [95% confidence interval] for 50 units increase in CLL: .97 [.68; 1.38], P = .88). Consistently, we found no correlations between CLL and all changes in cardiometabolic risk factors and nutritional parameters.
In a proximal RYGB, CLL does not influence hypertension remission, cardiometabolic risk factors, and nutritional parameters.
尽管 Roux-en-Y 胃旁路术（RYGB）可显著减轻体重并改善心血管代谢风险因素，但肢体长度是否会影响这些结果尚未达成共识。
评估共同肢体长度（CLL）与 RYGB 后高血压缓解率、心血管代谢风险因素和营养参数之间的相关性。
巴西私立医院。
GATEWAY 是一项随机试验，旨在评估 RYGB 对 I 级和 II 级肥胖患者高血压改善和其他心血管代谢风险因素的疗效，与药物治疗相比。随访时间为 1 年。我们测量了所有患者的整个肠道，并使用了 150cm 的肠内肢体和 100cm 的胆胰肢体。使用单变量逻辑回归来估计 CLL 与高血压缓解之间的关系。使用 Pearson 和 Spearman 相关系数评估 CLL 与心血管代谢风险因素和营养参数的百分比变化之间的相关性。
在 100 名随机患者中，有 45 名接受了 RYGB 并完成了随访。平均 CLL 为 466.3±86.4cm。RYGB 组中 55.6%的患者高血压缓解。CLL 长度与高血压缓解无显著相关性（CLL 增加 50 个单位的优势比[95%置信区间]：0.97[0.68；1.38]，P=0.88）。同样，我们发现 CLL 与心血管代谢风险因素和营养参数的所有变化之间均无相关性。
在近端 RYGB 中，CLL 不影响高血压缓解、心血管代谢风险因素和营养参数。
